Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.41 |
| ▸ | PARP1 | P09874 | 7/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.39 |
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13063713 | 1.00 | NFKB1 (0.59) | NFKB1NFKB2RELAEPHX2PARP1 | |
| SCHEMBL14923296 | 0.98 | NFKB1 (0.57) | NFKB1NFKB2RELAEPHX2PARP1 | |
| SCHEMBL23522374 | 0.94 | NFKB1 (0.59) | NFKB1NFKB2RELAEPHX2PARP1 | |
| SCHEMBL29362349 | 0.94 | NFKB1 (0.59) | NFKB1NFKB2RELAEPHX2PARP1 | |
| SCHEMBL8734157 | 0.92 | NFKB1 (0.49) | NFKB1NFKB2RELAEPHX2PARP1 | |
| SCHEMBL29359665 | 0.90 | NFKB1 (0.55) | NFKB1NFKB2RELAEPHX2PARP1 | |
| Alterporriol A/B SCHEMBL30948399 | 0.89 | NFKB1 (0.59) | NFKB1NFKB2RELAEPHX2PARP1 | |
| Alterporriol G/H SCHEMBL15338594 | 0.88 | NFKB1 (0.55) | NFKB1NFKB2RELAEPHX2PARP1 | |
| Alterporriol G/H SCHEMBL904379 | 0.88 | NFKB1 (0.55) | NFKB1NFKB2RELAEPHX2PARP1 | |
| SCHEMBL23522462 | 0.87 | NFKB1 (0.67) | NFKB1NFKB2RELAPARP1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435394-B1 | NOVEL ANTHRAQUINONE DERIVATIVES | SEALIFE PHARMA GMBH (AT) | 2013-05-08 | — | — | EP | claimed |
| US-20120129927-A1 | New Anthraquinone Derivatives | SEALIFE PHARMA GMBH (AT) | 2012-05-24 | — | — | US | claimed |
| EP-2435394-B1 | NOVEL ANTHRAQUINONE DERIVATIVES | SEALIFE PHARMA GMBH (AT) | 2013-05-08 | — | — | EP | disclosed |
| EP-2435394-B1 | NOVEL ANTHRAQUINONE DERIVATIVES | SEALIFE PHARMA GMBH (AT) | 2013-05-08 | — | — | EP | disclosed |
| CN-102482188-A | Novel anthraquinone derivatives | SEALIFE PHARMA GMBH | 2012-05-30 | — | — | CN | disclosed |
| US-20120129927-A1 | New Anthraquinone Derivatives | SEALIFE PHARMA GMBH (AT) | 2012-05-24 | — | — | US | disclosed |
| US-20120129927-A1 | New Anthraquinone Derivatives | SEALIFE PHARMA GMBH (AT) | 2012-05-24 | — | — | US | disclosed |
| US-20120129927-A1 | New Anthraquinone Derivatives | SEALIFE PHARMA GMBH (AT) | 2012-05-24 | — | — | US | disclosed |
| US-20120129927-A1 | New Anthraquinone Derivatives | SEALIFE PHARMA GMBH (AT) | 2012-05-24 | — | — | US | disclosed |
| EP-2435394-A1 | NOVEL ANTHRAQUINONE DERIVATIVES | Sealife Pharma GmbH (AT) | 2012-04-04 | — | — | EP | disclosed |
| WO-2010135759-A1 | NOVEL ANTHRAQUINONE DERIVATIVES | SEALIFE PHARMA GMBH (AT) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010135759-A1 | NOVEL ANTHRAQUINONE DERIVATIVES | SEALIFE PHARMA GMBH (AT) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129927-A1 | New Anthraquinone Derivatives | ANXA1, ANTXR2, ANXA11 | NFKB1 1413/4885NFKB2 1824/4885RELA 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.